Aspirin for prevention of adverse pregnancy outcome in women with elevated alfa-feto protein

Aspirin for prevention of adverse pregnancy outcome in women with elevated alfa-feto protein in second trimester screening,a randomised clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201203018954N1

Enrollment

109

Registered

2012-06-05

Start date

2012-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated level of alfa fetoprotein in second trimester screening.

Interventions

Intervention 1: aspirin usage. Intervention 2: Anomaly scan ultrasonography and routine prenatal care is done.

Treatment - Drugs

aspirin usage

Anomaly scan ultrasonography and routine prenatal care is done

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusin criteria:16-20 gestational weeks pregnant women who attend Imam khomeini hospital clinic of perinatology,and have a second trimester AFP>2.5 MOM.They are divided into 2 groups with or without aspirin. Patients are included in study who deliver in Imam khomeini hospital. Exclusion criteria :maternal medical disease and uterus anomalies

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Preeclampcia. Timepoint: >20 weeks gestation. Method of measurement: BP>=140/90 and 300 mg protein in 24 hour urine or ++ in a urine analysis.;Intrauterine growth restriction. Timepoint: Due to clinical condition evaluate every 4 weeks. Method of measurement: Biometry with sonography and nomograms.	—

Secondary

Measure	Time frame
NICU admission of neonate. Timepoint: NICU admission after delivery in first 28 days of birth. Method of measurement: hospital records.;Neonatal moratlity. Timepoint: Mortality of neonate in first 28 day of birth. Method of measurement: Hospital records.;Oligohydramnios. Timepoint: >20 weeks gestation. Method of measurement: Ultrasonography.;Placenta accreta. Timepoint: In pregnancy. Method of measurement: Clinical or with ultrasonography.;Hysterectomy. Timepoint: Removal of uterus after delivery. Method of measurement: Clinical.;Relationship between increased uterine artery pulsatory index and adverse pregnancy outcome. Timepoint: Ultrasonography in 16-20 weeks gestation. Method of measurement: Doppler ultrasound of uterine arteries.	—

Measure

Time frame

NICU admission of neonate. Timepoint: NICU admission after delivery in first 28 days of birth. Method of measurement: hospital records.;Neonatal moratlity. Timepoint: Mortality of neonate in first 28 day of birth. Method of measurement: Hospital records.;Oligohydramnios. Timepoint: >20 weeks gestation. Method of measurement: Ultrasonography.;Placenta accreta. Timepoint: In pregnancy. Method of measurement: Clinical or with ultrasonography.;Hysterectomy. Timepoint: Removal of uterus after delivery. Method of measurement: Clinical.;Relationship between increased uterine artery pulsatory index and adverse pregnancy outcome. Timepoint: Ultrasonography in 16-20 weeks gestation. Method of measurement: Doppler ultrasound of uterine arteries.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr soghra khazardoost

Imam khomeini hospital

drkhazardoost@yahoo.com+216 1192482

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026